For: | Olagunju A, Yamani N, Kenny D, Mookadam M, Mookadam F, Unzek S. Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World J Cardiol 2022; 14(11): 599-616 [PMID: 36483765 DOI: 10.4330/wjc.v14.i11.599] |
---|---|
URL: | https://www.wjgnet.com/1949-8462/full/v14/i11/599.htm |
Number | Citing Articles |
1 |
І. М. Кліщ. МЕТАБОЛІЧНИЙ СИНДРОМ: ПОГЛЯД НА ПРОБЛЕМУ. Здобутки клінічної і експериментальної медицини 2024; (1): 17 doi: 10.11603/1811-2471.2024.v.i1.14523
|
2 |
Maria Cristina Costa de Almeida, Marildes Luiza Castro, Larissa Espíndola, Luciana Nicolau Aranha, Thaís Salim, Gláucia Maria Moraes de Oliveira. One Size Does Not Fit All: The Need to Rethink the Metabolic Syndrome in Women. International Journal of Cardiovascular Sciences 2023; 36 doi: 10.36660/ijcs.20230101
|
3 |
Lance Sloan. SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review. Postgraduate Medicine 2024; 136(8): 801 doi: 10.1080/00325481.2024.2418795
|
4 |
Lubna Islam, Dhanya Jose, Mohammed Alkhalifah, Dania Blaibel, Vishnu Chandrabalan, Joseph M Pappachan. Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience. World Journal of Diabetes 2024; 15(3): 463-474 doi: 10.4239/wjd.v15.i3.463
Abstract(412) |
Core Tip(460) |
Full Article(HTML)(2082)
|
Full Article with Cover (PDF)-1271K(119)
|
Full Article (Word)-381K(1)
|
Audio-1428K(10)
|
Peer-Review Report-175K(57)
|
Answering Reviewers-179K(49)
|
Full Article (PDF)-893K(188)
|
Full Article (XML)-122K(58)
|
Times Cited (2)
|
Total Visits (6109)
|
Open
|